WILLIAM BARRY WHITE

Summary

Affiliation: University of Connecticut Health Center
Country: USA

Publications

  1. request reprint
    White W, Kent J, Taylor A, Verburg K, Lefkowith J, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-34 pubmed
    ..The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients. ..
  2. request reprint
    White W, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347-53 pubmed
    ..These results demonstrate that telmisartan achieved a greater effect than valsartan on BP during the early morning period in patients with hypertension. ..
  3. request reprint
    White W. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007;13:34-9 pubmed
  4. White W. Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. Am J Med. 2008;121:S2-7 pubmed publisher
  5. White W, Littlejohn T, Majul C, Oigman W, Olvera R, Seeber M, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit. 2010;15:205-12 pubmed publisher
    ..These findings show that telmisartan and amlodipine in combination provide substantial 24-h BP efficacy that is superior to either monotherapy in patients with stages 1 and 2 hypertension. ..
  6. White W, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:668-73 pubmed publisher
    ..Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus. ..
  7. White W, Turner J, Sica D, Bisognano J, Calhoun D, Townsend R, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014;8:743-57 pubmed publisher
  8. request reprint
    White W, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48:246-53 pubmed
    ..These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension. ..
  9. White W, Schnitzer T, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104:840-5 pubmed publisher
    ..04), naproxcinod 375 mg (14%, p = 0.055), and placebo (15.6%, p = 0.155). In conclusion, naproxcinod did not induce elevations of BP seen with naproxen, and it had similar effects on BP to that of placebo in patients with osteoarthritis. ..

More Information

Publications15

  1. White W, Wolfson L, Wakefield D, Hall C, Campbell P, Moscufo N, et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. Circulation. 2011;124:2312-9 pubmed publisher
    ..The 24-hour systolic BP may be a potential target for intervention in the elderly to reduce vascular disease of the brain and impairment of function. ..
  2. request reprint
    White W, Pitt B, Preston R, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112:1979-84 pubmed
    ..This characteristic may lead to benefit for cardiovascular risk reduction in this population. ..
  3. White W, Bresalier R, Kaplan A, Palmer B, Riddell R, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12:765-75 pubmed publisher
    ..At the registered doses of 150 mg and 300 mg daily, aliskiren has safety and tolerability profiles similar to placebo, other RAS blockers, and diuretics. Cough rates are lower with aliskiren compared with ACE inhibitors. ..
  4. White W, Cooke G, Kowey P, Calverley P, Bredenbröker D, Goehring U, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144:758-765 pubmed publisher
    ..Potential cardiovascular benefits of roflumilast should be evaluated in future controlled clinical trials. ..
  5. White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35 pubmed publisher
    ..Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.). ..
  6. White W, Marfatia R, Schmidt J, Wakefield D, Kaplan R, Bohannon R, et al. INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY). Am Heart J. 2013;165:258-265.e1 pubmed publisher
    ..The INFINITY trial is the first to guide antihypertensive therapy using ABP monitoring rather than clinic BP to reduce cerebrovascular disease...